PT891187E - Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos - Google Patents

Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos

Info

Publication number
PT891187E
PT891187E PT97916410T PT97916410T PT891187E PT 891187 E PT891187 E PT 891187E PT 97916410 T PT97916410 T PT 97916410T PT 97916410 T PT97916410 T PT 97916410T PT 891187 E PT891187 E PT 891187E
Authority
PT
Portugal
Prior art keywords
pct
beta
derivatives
carbolinos
antimestatic
Prior art date
Application number
PT97916410T
Other languages
English (en)
Inventor
Silvano Spinelli
Ernesto Menta
Hans-Willi Krell
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI960664 external-priority patent/IT1283574B1/it
Priority claimed from IT96MI002241 external-priority patent/IT1286060B1/it
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT891187E publication Critical patent/PT891187E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
PT97916410T 1996-04-04 1997-03-27 Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos PT891187E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI960664 IT1283574B1 (it) 1996-04-04 1996-04-04 Uso di derivati beta-carbolinici come agenti antimetastatici
IT96MI002241 IT1286060B1 (it) 1996-10-29 1996-10-29 Uso di derivati tetraidro-beta-carbolinici come agenti antimetastatici

Publications (1)

Publication Number Publication Date
PT891187E true PT891187E (pt) 2002-06-28

Family

ID=26331376

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97916410T PT891187E (pt) 1996-04-04 1997-03-27 Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos

Country Status (15)

Country Link
US (1) US6069150A (pt)
EP (1) EP0891187B1 (pt)
JP (1) JP2000508302A (pt)
KR (1) KR20000005175A (pt)
CN (1) CN1113648C (pt)
AT (1) ATE212549T1 (pt)
AU (1) AU710079B2 (pt)
BR (1) BR9708480A (pt)
CA (1) CA2250898A1 (pt)
DE (1) DE69710182T2 (pt)
DK (1) DK0891187T3 (pt)
ES (1) ES2169857T3 (pt)
PT (1) PT891187E (pt)
TR (1) TR199801970T2 (pt)
WO (1) WO1997037658A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040253891A1 (en) * 2000-09-12 2004-12-16 Schierenbeck Alan W. Composite structure for protective garment
US6720331B2 (en) 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
CA2441792C (en) * 2001-04-25 2010-08-03 Lilly Icos Llc Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
ATE348828T1 (de) * 2001-10-19 2007-01-15 Transtech Pharma Inc Beta-carbolin-derivate als ptp-inhibitoren
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
EP1706404A2 (en) * 2004-01-23 2006-10-04 Chiron Corporation Tetrahydrocarboline compounds as anticancer agents
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
EP1737461B1 (en) * 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
CN100360129C (zh) * 2004-09-03 2008-01-09 首都医科大学 去氢胡秃子碱衍生物、其合成方法及其应用
WO2006070385A1 (en) * 2004-12-27 2006-07-06 Council Of Scientific And Industrial Research 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
ITMI20071163A1 (it) * 2007-06-08 2008-12-09 C4T S C A R L Arilsolfonammidi dela beta-carbolina metodo per prepararle e composizione che le comprende
BRPI0906244A2 (pt) 2008-03-24 2015-06-30 Medivation Technologies Inc Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
CA2999345A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120136154A1 (en) 2009-05-27 2012-05-31 Peter Seongwoo Hwang Processes for the preparation of substituted tetrahydro beta-carbolines
CN101906102B (zh) * 2009-06-02 2012-08-29 首都医科大学 β-咔啉类生物碱衍生物及其制备方法和应用
US9169247B2 (en) 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
CN104744460B (zh) * 2013-12-30 2017-06-16 南开大学 β‑咔啉，二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
CA2972065A1 (en) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
EP3436005A4 (en) * 2016-03-29 2020-07-22 Georgia State University Research Foundation, Inc. CALCIUM DETECTION RECEPTORS, LIGANDS, COMPOSITIONS AND PROCEDURES FOR USE
MX2019012385A (es) * 2017-04-17 2022-03-15 Ampersand Biopharmaceuticals Llc Administración parenteral no sistémica de agentes amortiguadores para inhibir la metástasis de tumores sólidos, hiperpigmentación y gota.
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3395M (fr) * 1963-07-30 1965-06-28 Roussel Uclaf Nouveau médicament notamment pour le traitement des états neurodépressifs et des psychoses d'anxiété.
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4539407A (en) * 1983-12-13 1985-09-03 American Home Products Corporation β-Carboline anticonvulsants
US5162336A (en) * 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5244905A (en) * 1990-08-31 1993-09-14 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives
CA2136108A1 (en) * 1993-03-18 1994-09-29 Makoto Sakamoto Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
EP0891187A1 (en) 1999-01-20
ES2169857T3 (es) 2002-07-16
AU710079B2 (en) 1999-09-16
EP0891187B1 (en) 2002-01-30
AU2506997A (en) 1997-10-29
CN1113648C (zh) 2003-07-09
WO1997037658A1 (en) 1997-10-16
CA2250898A1 (en) 1997-10-16
ATE212549T1 (de) 2002-02-15
US6069150A (en) 2000-05-30
DE69710182D1 (de) 2002-03-14
TR199801970T2 (xx) 2000-10-23
DK0891187T3 (da) 2002-04-29
BR9708480A (pt) 1999-04-13
KR20000005175A (ko) 2000-01-25
JP2000508302A (ja) 2000-07-04
DE69710182T2 (de) 2002-08-29
CN1215333A (zh) 1999-04-28

Similar Documents

Publication Publication Date Title
PT891187E (pt) Utilizacao de derivados de tetrahidro-beta-carbolinos como agentes antimestaticos
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
DE69621831T2 (de) Piperazinderivative als tachykinin antagonisten
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
BG106340A (en) Substituted oxoazaheterocyclyl compounds
AU1973997A (en) Pentafluorobenzenesulfonamides and analogs
TR200003094T2 (tr) Glukokortikoid-seçimli enflamasyon önleyici maddeler.
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
ES2193154T3 (es) Procedimiento para la preparacion de 9-desoxotaxanos.
TR200000025T2 (tr) Azetidinilpropilpiperidin türevleri, ara bağlarıyla tacikinin antagonistleri olarak kullanımları.
ES2193414T3 (es) Dihidrobenzofuranos sustituidos como inhibidores de la pde.
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
TR200001452T2 (tr) Bifenilamidin türevleri.
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
ES2143224T3 (es) Derivados naftamida de 3-beta-amino azabiciclo octano o nonano, como agentes antipsicoticos.
DE69828390D1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
DK0790994T3 (da) Heterocyclisk substituerede propensyrederivater som NMDA-antagonister
DK0883628T3 (da) 17beta- (2-oxo-tetrahydrofuran-4-yl) -thioandrostanderivater (17beta- (gamma-smørsyrelacton) -thioderivater) til behandling
PT914129E (pt) Utilizacao de aspirocloro ou derivados seus como agentes imunossupresivos
PT1140932E (pt) Derivados de 1,8-benzonaftiridina